Pargluva
Treatment for Diabetes Type 2Bristol-Myers Squibb Provides Regulatory Update for Muraglitazar
PRINCETON, N.J., December 23, 2004 -- Bristol-Myers Squibb Company today announced that the company submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for muraglitazar, an investigational agent under development for the treatment of patients with type 2 diabetes. Bristol-Myers Squibb and Merck & Co., Inc. are collaborators in the global development and commercialization of muraglitazar.
Muraglitazar, discovered by Bristol-Myers Squibb, has the potential to be the first in a novel class of drugs known as dual peroxisome proliferator activated receptor (PPAR) agonists to be approved for marketing in the U.S.
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
For further information, please visit www.bms.com
Posted: December 2004
Related Articles
- Bristol-Myers Squibb Statement on Muraglitazar, an Investigational Oral Treatment For Type 2 Diabetes - October 27, 2005
- Bristol-Myers Squibb and Merck Joint Statement on Regulatory Status of Pargluva (Muraglitazar), an Investigational Oral Treatment for Type 2 Diabetes - October 18, 2005
- Bristol-Myers Squibb and Merck Joint Statement on FDA Advisory Committee Vote on Pargluva (Muraglitazar), an Investigational Oral Treatment for Type 2 Diabetes - September 9, 2005
Pargluva (muraglitazar) FDA Approval History
